- Home
- Equipment
- usa minnesota
- platelet aggregation
Refine by
Platelet Aggregation Equipment Supplied In Usa Minnesota
5 equipment items found
by:Hemostasis, Llc based inSaint Paul, MINNESOTA (USA)
Different Platforms for Your Individual Needs.Recognizing that each surgeon’s preferences and the anatomy of each patient’s sinuses are not identical, Hemostasis has developed multiple platforms of our PosiSep® hemostat sinus splints to meet those varying needs. ...
by:Hemostasis, Llc based inSaint Paul, MINNESOTA (USA)
Different Platforms for Your Individual Needs. Recognizing that each surgeon’s preferences and the anatomy of each patient’s sinuses are not identical, Hemostasis has developed multiple platforms of our PosiSep® hemostat sinus splints to meet those varying needs. ...
Manufactured by:Carbon Medical Technologies, Inc. based inSt. Paul, MINNESOTA (USA)
Durasphere is an injectable bulking agent containing pyrolytic carbon-coated graphite beads suspended in a water-based carrier gel containing beta glucan. It is used in the treatment of stress urinary incontinence. Durasphere is a highly biocompatible, permanent material that can be administered in less than 30 minutes in a simple office-based ...
Manufactured by:United Therapeutics Corporation based inSilver Spring, MARYLAND (USA)
Remodulin is a prostacyclin vasodilator indicated for the treatment of pulmonary arterial hypertension (PAH; WHO Group 1) to diminish symptoms associated with exercise. Studies establishing effectiveness included patients with NYHA Functional Class II-IV symptoms and etiologies of idiopathic or heritable PAH (58%), PAH associated with congenital systemic-to-pulmonary shunts (23%), or PAH ...
Manufactured by:United Therapeutics Corporation based inSilver Spring, MARYLAND (USA)
TYVASO (treprostinil) is a prostacyclin mimetic indicated for the treatment of: Pulmonary arterial hypertension (PAH; WHO Group 1) to improve exercise ability. Studies establishing effectiveness predominately included patients with NYHA Functional Class III symptoms and etiologies of idiopathic or heritable PAH (56%) or PAH associated with connective tissue diseases (33%). The effects diminish ...